文献速递肾小球疾病慢性肾脏病

纯狼疮性膜性肾病的治疗反应结局与预测因素

Outcomes and Predictors of Treatment Response in Patients With Pure Lupus Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2026-07-08

这项法国25中心回顾性研究纳入194例活检证实的初发纯狼疮性膜性肾病患者,评估不同初始治疗策略的12个月肾脏缓解率。结果显示免疫抑制方案间12个月肾脏缓解率无显著差异,但抗U1RNP抗体与治疗失败独立相关,而肾外狼疮受累为保护因素;利妥昔单抗方案与更短疗程和节省激素相关。

要点

  • 抗U1RNP抗体阳性者12个月治疗失败风险更高(调整OR 2.53)。
  • 无肾外狼疮受累与治疗失败风险升高独立相关(调整OR 0.39)。
  • 利妥昔单抗方案与更短治疗时长和节省糖皮质激素相关。

核心结论

  • 初发纯狼疮性膜性肾病患者12个月肾脏缓解率在不同免疫抑制方案间无显著差异。
  • 抗U1RNP抗体与治疗失败风险升高独立相关,而肾外狼疮受累与治疗失败风险降低独立相关。
  • 基于抗CD20的策略可能是 promising 的治疗选择。

研究设计与样本

  • 多中心回顾性研究,纳入法国25个中心2000至2020年间活检证实的初发纯狼疮性膜性肾病患者194例。
  • 按初始治疗策略分组:支持治疗53例(27.3%),免疫抑制治疗141例(72.7%)。
  • 免疫抑制治疗中,MMF方案54例(38.3%),利妥昔单抗方案26例(18.4%),其他方案61例(43.3%)。
  • 肾脏缓解率依据2024年KDIGO指南定义,采用logistic回归分析12个月治疗失败相关因素。

主要发现

  • 12个月完全肾脏缓解率:支持治疗36.7%,MMF 47.1%,利妥昔单抗64.0%,其他方案45.4%。
  • 12个月完全或部分肾脏缓解率:支持治疗55.1%,MMF 60.8%,利妥昔单抗72.0%,其他方案54.5%。
  • 多变量分析中,抗U1RNP抗体与治疗失败独立相关(调整OR 2.53;95%CI 1.35-4.70;P=0.004)。
  • 肾外狼疮受累与治疗失败风险降低独立相关(调整OR 0.39;95%CI 0.19-0.73;P=0.004)。
  • 利妥昔单抗方案与更短治疗时长和节省糖皮质激素显著相关。

关键数值与推荐

  • 肾脏缓解率定义依据2024年KDIGO指南。
  • 12个月完全肾脏缓解率利妥昔单抗组64.0%,MMF组47.1%,支持治疗组36.7%,其他方案组45.4%。
  • 12个月完全或部分肾脏缓解率利妥昔单抗组72.0%,MMF组60.8%,支持治疗组55.1%,其他方案组54.5%。

临床怎么用

  • 对初发纯狼疮性膜性肾病患者,可考虑利妥昔单抗为基础的方案,其与更短疗程和节省激素相关。
  • 抗U1RNP抗体阳性提示治疗失败风险较高,需加强监测和随访。
  • 无肾外狼疮受累的患者治疗失败风险亦较高,应予以关注。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 各组样本量不均衡,利妥昔单抗组仅26例。
  • 12个月随访时间较短,缺乏长期肾脏结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The indications and modalities of therapeutic strategies for first-onset pure lupus membranous nephropathy (PLMN) remain poorly defined. We aimed to evaluate renal response rates across real-world treatment strategies and identify predictors of treatment response in PLMN. METHODS: We conducted a multicenter retrospective study in 25 French centers. Patients with biopsy-proven first-onset PLMN treated between 2000 and 2020 were included. Patients were classified according to their initial treatment strategy. Renal response rates were defined based on the 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Factors associated with treatment failure at 12 months were assessed using logistic regression. RESULTS: Among 194 patients with PLMN, 53 (27.3%) received supportive care only, and 141 (72.7%) received immunosuppressive therapy (54 [38.3%] received mycophenolate mofetil (MMF)-based regimens, 26 [18.4%] received rituximab [RTX]-based regimens, and 61 [43.3%] received other treatments). At 12 months, rates of complete renal response (CRR) and CRR or partial renal (PRR) were respectively, 36.7% and 55.1% with supportive care, 47.1% and 60.8% with MMF, 64.0% and 72.0% with RTX, and 45.4% and 54.5% with other regimens. In multivariable analysis, the presence of anti-U1-ribonucleoprotein (U1RNP) antibodies was independently associated with treatment failure (adjusted odds ratio [OR]: 2.53; 95% confidence interval [CI]: 1.35-4.70; P = 0.004), whereas extrarenal lupus involvement was protective (adjusted OR = 0.39; 95% CI: 0.19-0.73; P = 0.004). RTX-based regimens were significantly associated with shorter treatment duration and corticosteroid sparing. CONCLUSION: In patients with first-onset PLMN, 12-month renal response rates did not differ significantly among immunosuppressive regimens despite variation in treatment duration and steroid exposure. Anti-U1RNP antibodies and absence of extrarenal involvement were associated with a higher risk of treatment failure. Anti-CD20-based strategies may be a promising therapeutic approach.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chevalier K, Brousse R, Karras A, et al. Outcomes and Predictors of Treatment Response in Patients With Pure Lupus Membranous Nephropathy. Kidney Int Rep. 2026. PMID: 42494786. doi:10.1016/j.ekir.2026.106678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。